NCT03103256 is a Phase 3 clinical trial of YHP1701 in Hypertension and Hyperlipidemia, sponsored by Yuhan Corporation.

Who is sponsoring NCT03103256?

NCT03103256 is sponsored by Yuhan Corporation.

What drugs are being tested in NCT03103256?

Interventions in NCT03103256: YHP1701, YHR1703, YHR1704.

What condition does NCT03103256 study?

NCT03103256 studies Hypertension and Hyperlipidemia.

Is NCT03103256 still recruiting?

NCT03103256 is currently completed. Last updated 7 September 2018.

Last reviewed 2018-09-07 · How we verify

NCT03103256

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Completed Phase 3 Last updated 7 September 2018

What this trial tests

Phase 3 trial testing YHP1701 in Hypertension and Hyperlipidemia in 106 participants. Completed in 30 April 2018.

Timeline

17 May 2017

Primary endpoint
30 April 2018

30 April 2018

Quick facts

Lead sponsor	Yuhan Corporation
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	106
Start date	17 May 2017
Primary completion	30 April 2018
Estimated completion	30 April 2018
Sites	1 location across South Korea

Drugs / interventions tested

YHP1701 — full drug profile →
YHR1703 — full drug profile →
YHR1704 — full drug profile →

Conditions studied

Hypertension and Hyperlipidemia — all drugs for Hypertension and Hyperlipidemia →

Sponsor

Yuhan Corporation — full company profile →

Who can join

19 and older, any sex, with Hypertension and Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
Kim W, Chang K, Cho EJ, Ahn JC, et al · · 2020 · cited 19× · PMID 32003938 · DOI 10.1111/jch.13774

Verify or expand the search:

Other Yuhan Corporation trials

Trials by the same sponsor.

NCT07470125 — Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07415551 — Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1- · Phase 2 · recruiting
NCT07265167 — Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed
NCT07111468 — Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis · Phase 3 · completed
NCT06920719 — Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03103256 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yuhan Corporation
Last refreshed: 7 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03103256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing